JP2015529657A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529657A5
JP2015529657A5 JP2015525760A JP2015525760A JP2015529657A5 JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5 JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5
Authority
JP
Japan
Prior art keywords
conditions
cancer
diseases
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529657A (ja
JP6374384B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/002032 external-priority patent/WO2014023385A1/en
Publication of JP2015529657A publication Critical patent/JP2015529657A/ja
Publication of JP2015529657A5 publication Critical patent/JP2015529657A5/ja
Application granted granted Critical
Publication of JP6374384B2 publication Critical patent/JP6374384B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525760A 2012-08-07 2013-07-10 プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 Active JP6374384B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12005716.1 2012-08-07
EP12005716 2012-08-07
PCT/EP2013/002032 WO2014023385A1 (en) 2012-08-07 2013-07-10 Pyridopyrimidine derivatives as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076582A Division JP2018150307A (ja) 2012-08-07 2018-04-12 プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2015529657A JP2015529657A (ja) 2015-10-08
JP2015529657A5 true JP2015529657A5 (it) 2017-09-28
JP6374384B2 JP6374384B2 (ja) 2018-08-15

Family

ID=48782275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015525760A Active JP6374384B2 (ja) 2012-08-07 2013-07-10 プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
JP2018076582A Pending JP2018150307A (ja) 2012-08-07 2018-04-12 プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018076582A Pending JP2018150307A (ja) 2012-08-07 2018-04-12 プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体

Country Status (10)

Country Link
US (1) US9725462B2 (it)
EP (1) EP2882746B1 (it)
JP (2) JP6374384B2 (it)
CN (1) CN104507942B (it)
AR (1) AR092365A1 (it)
AU (1) AU2013301865B2 (it)
CA (1) CA2881279C (it)
ES (1) ES2618004T3 (it)
IL (1) IL237073A (it)
WO (1) WO2014023385A1 (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
US9725462B2 (en) * 2012-08-07 2017-08-08 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
KR20140027714A (ko) * 2012-08-27 2014-03-07 주식회사 홍인터내셔날 외부 디바이스와 연동하는 다트 게임 장치
CA2993096C (en) 2015-07-21 2022-04-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
CA3030167A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112019012589B1 (pt) 2016-12-22 2022-11-29 Calithera Biosciences Inc Compostos e composição farmacêutica para uso no tratamento de câncer por meio da inibição de atividade de arginase e processo para a produção de composto
WO2018136264A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
KR20190111079A (ko) 2017-01-23 2019-10-01 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 이환 화합물
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3652174A4 (en) * 2017-07-13 2021-06-30 Syros Pharmaceuticals, Inc. TAM KINASE INHIBITORS
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP6995025B2 (ja) 2018-08-09 2022-02-04 株式会社豊田自動織機 太陽熱集熱管
CN110833557A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗肾小管肾炎的用途
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020280024A1 (en) 2019-05-21 2021-12-09 Amgen Inc. Solid state forms
JP7357146B2 (ja) * 2019-08-22 2023-10-05 ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド アザヘテロアリール化合物及びその使用
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4107146A1 (en) * 2020-02-17 2022-12-28 Alesta Therapeutics BV Gcn2 modulator compounds
CN115003671A (zh) * 2020-09-07 2022-09-02 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
WO2022079250A1 (en) 2020-10-16 2022-04-21 Merck Patent Gmbh Compounds for the treatment of viral infections
CN117180122B (zh) * 2023-11-02 2024-04-09 杭州湃肽生化科技有限公司 一种舒敏修复组合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752141T2 (de) * 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CZ200331A3 (cs) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
JP5802127B2 (ja) 2008-04-16 2015-10-28 ポートラ ファーマシューティカルズ, インコーポレイテッド Syk又はjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド類
CN102083438B (zh) 2008-05-01 2016-11-09 西特里斯药业公司 作为沉默信息调节因子的调节剂的喹啉和相关类似物
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
KR20110093923A (ko) 2008-12-01 2011-08-18 메르크 파텐트 게엠베하 암에 대한 오토탁신 저해제로서의 2,5-디아미노-치환된 피리도 [4,3-d]피리미딘
US8404677B2 (en) * 2009-10-29 2013-03-26 Genosco Kinase inhibitors
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US9725462B2 (en) * 2012-08-07 2017-08-08 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2015529657A5 (it)
JP2015508086A5 (it)
JP2015508099A5 (it)
JP2015509512A5 (it)
JP2016128501A5 (it)
JP2015508085A5 (it)
JP2020528889A5 (it)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
WO2016044331A1 (en) Bicyclic compounds
JP2018520205A5 (it)
JP2014507455A5 (it)
JP2012532874A5 (it)
JP2015511609A5 (it)
JP2014515013A5 (it)
JP2019524883A5 (it)
JP2014114295A5 (it)
JP2010523522A5 (it)
TW200523250A (en) Compounds for inflammation and immune-related uses
JP2017504635A5 (it)
RU2019126848A (ru) Способы производства дейтерий-обогащённого N-ацетилцистеин амида (D-NACA) и (2R,2R')-3,3'-дисульфанедиил бис(2-ацетамидопропанамида) (DINACA) и применение D-NACA и DINACA для лечения заболеваний, включающих окислительный стресс
JP2016511753A5 (it)
RU2015137978A (ru) Способы ингибирования лейкотриен- а4-гидролазы
JP2006510603A (ja) R−非ステロイド性抗炎症薬エステル及びそれらの使用
JP2008501722A5 (it)
JP2016505058A5 (it)